KR100291377B1 - - Google Patents

Info

Publication number
KR100291377B1
KR100291377B1 KR19940703547A KR19940703547A KR100291377B1 KR 100291377 B1 KR100291377 B1 KR 100291377B1 KR 19940703547 A KR19940703547 A KR 19940703547A KR 19940703547 A KR19940703547 A KR 19940703547A KR 100291377 B1 KR100291377 B1 KR 100291377B1
Authority
KR
South Korea
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR19940703547A
Other languages
Korean (ko)
Other versions
KR950700760A (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700760A publication Critical patent/KR950700760A/ko
Application granted granted Critical
Publication of KR100291377B1 publication Critical patent/KR100291377B1/ko
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019940703547A 1992-04-10 1994-10-07 CD33 관련 표면 항원에 대한 면역독소(Immunotoxins directed against CD33 related surface antigens) Granted KR950700760A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86669392A 1992-04-10 1992-04-10
PCT/US1993/003284 WO1993020848A1 (en) 1992-04-10 1993-04-08 Immunotoxins directed against cd33 related surface antigens

Publications (2)

Publication Number Publication Date
KR950700760A KR950700760A (ko) 1995-02-20
KR100291377B1 true KR100291377B1 (en:Method) 2001-09-17

Family

ID=25348185

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703547A Granted KR950700760A (ko) 1992-04-10 1994-10-07 CD33 관련 표면 항원에 대한 면역독소(Immunotoxins directed against CD33 related surface antigens)

Country Status (13)

Country Link
EP (2) EP1656950A1 (en:Method)
JP (1) JP3949158B2 (en:Method)
KR (1) KR950700760A (en:Method)
CN (1) CN1056084C (en:Method)
AU (1) AU675226B2 (en:Method)
CA (1) CA2133838C (en:Method)
FI (1) FI944730A0 (en:Method)
IL (1) IL105344A (en:Method)
NO (1) NO314686B1 (en:Method)
NZ (1) NZ252799A (en:Method)
RU (1) RU2127122C1 (en:Method)
WO (1) WO1993020848A1 (en:Method)
ZA (1) ZA932523B (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
DK1436003T3 (da) * 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2016201388A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
HK1252675A1 (zh) 2015-06-12 2019-05-31 Alector Llc 抗cd33抗體及其使用方法
EP3589658A1 (en) 2017-08-03 2020-01-08 Alector LLC Anti-cd33 antibodies and methods of use thereof
PE20211096A1 (es) 2018-08-31 2021-06-14 Alector Llc Anticuerpos anti-cd33 y metodos para usarlos
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
ES2152216T3 (es) * 1989-12-14 2001-02-01 Sloan Kettering Inst Cancer Usos terapeuticos de la region hipervariable del anticuerpo monoclonal m195 y constructos de la misma.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Int. J. Cancer Vol.43(1):152-157 (1989. 11) *
Leukemia Vol. 3(6):440-445 (1989. 6. ) *

Also Published As

Publication number Publication date
FI944730A7 (fi) 1994-10-07
EP1656950A1 (en) 2006-05-17
NZ252799A (en) 1996-10-28
NO314686B1 (no) 2003-05-05
EP0634938A4 (en) 1998-06-03
RU2127122C1 (ru) 1999-03-10
JP3949158B2 (ja) 2007-07-25
AU4280193A (en) 1993-11-18
FI944730L (fi) 1994-10-07
CA2133838C (en) 2003-07-29
NO943776L (no) 1994-11-25
CA2133838A1 (en) 1993-10-28
FI944730A0 (fi) 1994-10-07
CN1078401A (zh) 1993-11-17
IL105344A0 (en) 1993-08-18
ZA932523B (en) 1994-10-08
KR950700760A (ko) 1995-02-20
EP0634938A1 (en) 1995-01-25
JPH08501059A (ja) 1996-02-06
NO943776D0 (no) 1994-10-07
AU675226B2 (en) 1997-01-30
CN1056084C (zh) 2000-09-06
WO1993020848A1 (en) 1993-10-28
IL105344A (en) 2000-06-29

Similar Documents

Publication Publication Date Title
TW234798B (en:Method)
TW233274B (en:Method)
TW218404B (en:Method)
BR9304651A (en:Method)
KR100291377B1 (en:Method)
IN181752B (en:Method)
BR9207065A (en:Method)
TW238267B (en:Method)
BR9202713C1 (en:Method)
IN182636B (en:Method)
TW251314B (en:Method)
TW231374B (en:Method)
IN184968B (en:Method)
IN182376B (en:Method)
IN181208B (en:Method)
IN180766B (en:Method)
ECSDI920036S (en:Method)
IN179364B (en:Method)
ITMI920295A0 (en:Method)
AU2098792A (en:Method)
CN3011929S (en:Method)
AU2840792A (en:Method)
CN3011936S (en:Method)
CN3011935S (en:Method)
EP0564321A3 (en:Method)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20080313

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090313

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090313